ALLMedicine™ Hypogammaglobulinemia Center
Research & Reviews 506 results
https://clinicaltrials.gov/ct2/show/NCT00967785
May 13th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT00032513
May 13th, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...
https://clinicaltrials.gov/ct2/show/NCT02579967
May 13th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...
https://clinicaltrials.gov/ct2/show/NCT05357781
May 3rd, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053130
Journal of Clinical Immunology; Simón-Fuentes M, Sánchez-Ramón S et. al.
Apr 30th, 2022 - Common variable immunodeficiency disorders (CVID), the most common primary immune deficiency, includes heterogeneous syndromes characterized by hypogammaglobulinemia and impaired antibody responses. CVID patients frequently suffer from recurrent i...
Drugs 7 results see all →
Clinicaltrials.gov 17 results
https://clinicaltrials.gov/ct2/show/NCT00967785
May 13th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT02579967
May 13th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...
https://clinicaltrials.gov/ct2/show/NCT00032513
May 13th, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...
https://clinicaltrials.gov/ct2/show/NCT05357781
May 3rd, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...
https://clinicaltrials.gov/ct2/show/NCT05321407
Apr 11th, 2022 - Individuals with primary and secondary antibody immunodeficiency are at higher risk for severe COVID-19 disease. Humoral immunity is thought to be the predominant protection against COVID-19, however mRNA vaccines have been shown to elicit both an...
News 42 results
https://www.mdedge.com/dermatology/article/252371/autoimmune-diseases/interstitial-granulomatous-dermatitis-adverse
Katherine G. Beuerlein, BS, Elise D. Martin, MD et. al.
Mar 3rd, 2022 - The number of monoclonal antibodies developed for therapeutic use has rapidly expanded over the last decade due to their generally favorable adverse effect (AE) profiles and efficacy. 1 Tumor necrosis factor α inhibitors and general integrin antago.
https://www.medpagetoday.com/hematologyoncology/myeloma/97437
Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...
https://www.onclive.com/view/zanubrutinib-sbla-for-waldenstr-m-macroglobulinemia-accepted-in-china
Jan 21st, 2022 - The China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) as a treatment for adult patients with Waldenström macroglobulinemia.1 The application is supported by...
https://www.onclive.com/view/fda-approval-sought-for-teclistamab-for-relapsed-refractory-multiple-myeloma
Dec 29th, 2021 - A biologics license application seeking the approval of the off-the-shelf, T-cell redirecting bispecific antibody, teclistamab (JNJ-64007957), for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.1 The ap...
https://www.onclive.com/view/kahl-weighs-the-complexities-of-treatment-selection-in-indolent-lymphoma
Oct 6th, 2021 - Brad S. Kahl, MD Optimizing treatment for patients with indolent non-Hodgkin lymphoma (iNHL) has become a challenge as the frontline and recurrent treatment settings continue to evolve, said Brad S. Kahl, MD. "The management of [recurrent] indol...